Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.19 USD
0.00 (0.00%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.19 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Adaptimmune Therapeutics PLC [ADAP]
Reports for Purchase
Showing records 21 - 40 ( 123 total )
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Updated Data from Lead Program Released - Poster Presentation at ASCO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Reasons to Sit Down with These Healthcare/Biotech Management
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
General Conference 2022: Face To Face. Synopsis of Select Companies
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
2022 Priorities--A Year of Execution to Commercialization
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
As CAR-T Programs Scream "Look at Me" During ASH, We Look to the Future Impact of TCR-Ts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Continued Response with TCR. Median Duration not Reached
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T